Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, following vaccination in children at 2, 4, 6 and at 15–18 months

BACKGROUND: Availability of affordable inactivated polio vaccines (IPV) is of major importance to meet the increasing global supply needs. The results presented here demonstrate non-inferiority of a reduced-dose, aluminium hydroxide-adjuvanted IPV (IPV-Al) to standard IPV. METHODS: A phase 3, observ...

Descripción completa

Detalles Bibliográficos
Autores principales: Sáez-Llorens, Xavier, Thierry-Carstensen, Birgit, Stoey, Lina Saem, Sørensen, Charlotte, Wachmann, Henrik, Bandyopadhyay, Ananda S., Nielsen, Pernille Ingemann, Kusk, Mie Vestergaard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184674/
https://www.ncbi.nlm.nih.gov/pubmed/32273184
http://dx.doi.org/10.1016/j.vaccine.2020.02.066

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184674/
https://www.ncbi.nlm.nih.gov/pubmed/32273184
http://dx.doi.org/10.1016/j.vaccine.2020.02.066

Ejemplares similares